Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
Cancer Research UK · King's College Hospital · +16 more institutions
Abstract
Rituximab-based immunochemotherapy has improved outcomes in patients with follicular lymphoma. Obinutuzumab is a glycoengineered type II anti-CD20 monoclonal antibody. We compared rituximab-based chemotherapy with obinutuzumab-based chemotherapy in patients with previously untreated advanced-stage follicular lymphoma.
We randomly assigned patients to undergo induction treatment with obinutuzumab-based chemotherapy or rituximab-based chemotherapy. Patients with a response received maintenance treatment for up to 2 years with the same antibody that they had received in induction. The primary end point was investigator-assessed progression-free survival.
Citation impact
- FWCI
- 48.46
- Percentile
- 100%
- References
- 22
Authors
18- RMRobert MarcusCorresponding
Cancer Research UK, King's College Hospital, University College London, Ludwig-Maximilians-Universität München
- ADAndrew Davies
Cancer Research UK, University of Southampton, University College London, Ludwig-Maximilians-Universität München
- KAKiyoshi Ando
Tokai University, Cancer Research UK, University College London, Ludwig-Maximilians-Universität München
- WHWolfgang Hiddemann
Cancer Research UK, Christian-Albrechts-Universität zu Kiel, University College London, Ludwig-Maximilians-Universität München
- SOStephen Opat
Cancer Research UK, Monash Health, University College London, Monash University, Ludwig-Maximilians-Universität München
Topics & keywords
- Obinutuzumab
- Rituximab
- Medicine
- Follicular lymphoma
- Internal medicine
- Oncology
- Chemotherapy
- Hazard ratio
- Zero hunger